Tivantinib (ARQ197) in hepatocellular carcinoma
Camillo Porta(University of Pavia), Carlo Ganini, Palma Giglione(University of Pavia), Wanda Liguigli(Istituti Ospitalieri di Cremona), Ilaria Imarisio(University of Pavia), Alessandra Ferrari(Ospedale Policlinico San Martino), Francesca Reversi(University of Pavia)
Cited by 16
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2012|275